Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Blocking extracellular glycine uptake mediated by GlyT1 mitigates protoporphyria
Marc Liesa
Marc Liesa
View: Text | PDF
Commentary

Blocking extracellular glycine uptake mediated by GlyT1 mitigates protoporphyria

  • Text
  • PDF
Abstract

Accumulation of the light-reactive heme precursor protoporphyrin IX (PPIX) in blood causes protoporphyria, a disease characterized by severe pain resulting from sunlight exposure, as well as by the occurrence of liver failure in some patients. Thus, decreasing PPIX biosynthesis is a promising strategy to treat protoporphyria. In this issue of the JCI, Ducamp et al. report that inhibition of the glycine plasma membrane transporter GLYT1 using bitopertin decreased PPIX accumulation and ameliorated liver disease using human in vitro and mouse in vivo models. Their findings support the ongoing development of bitopertin to treat protoporphyria, while concurrently pointing to underexplored roles of glycine in erythroid cells.

Authors

Marc Liesa

×

Figure 1

EPP and XLPP induce PPIX accumulation by different mechanisms, but blocking glycine import with bitopertin can decrease PPIX accumulation in both forms.

Options: View larger image (or click on image) Download as PowerPoint
EPP and XLPP induce PPIX accumulation by different mechanisms, but block...
ALAS2 catalyzes glycine and succinyl-CoA into ALA in the first reaction of heme biosynthesis in erythroid cells, but not in hepatocytes. In a downstream reaction that occurs in both erythroid cells and hepatocytes, the enzyme FECH converts PPIX into heme. (A) Diminished FECH function in EPP is expected to induce a larger increase in PPIX in hepatocytes due to primary PPIX accumulation in both erythroid cells and hepatocytes. (B) However, in XLPP, ALAS2 gain of function leads to PPIX accumulation in erythroid cells only. (C) Illustration shows how bitopertin-mediated blockade of the glycine transporter limits glycine availability, preventing PPIX accumulation in both conditions. Notably, although limiting glycine availability and decreasing FECH in erythroid cells was predicted to be accompanied by decreased heme biosynthesis if PPIX were to decrease, this was not observed. This points to other mechanisms by which glycine contributes to heme homeostasis and by which erythroid cells can preserve heme content independently of FECH activity.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts